Key result
Metabolic and mineralocorticoid-targeting therapies deliver clearer cardiac benefits than classical hormone replacement.
Why the study?
The heart is both a target of hormonal regulation and a secretory organ, yet cardiology and endocrinology continue to describe these roles in largely separate literatures, leaving it unclear how far current data support an integrated network account.
This narrative review synthesizes evidence on bidirectional heart-endocrine communication, highlighting that therapeutic cardiovascular benefits along this axis derive primarily from modulating metabolic and mineralocorticoid signaling rather than classical hormone replacement.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in cardio-endocrine overlap; leaves open superiority of targeted modulation pending randomized trials.
The heart is simultaneously a target of hormonal regulation and a secretory organ whose products act at a distance, yet cardiology and endocrinology continue to describe these two roles in largely separate literatures. This critical narrative review examines the evidence for bidirectional communication between the heart and the endocrine system, from reversible physiological adaptation to established disease, and asks how far an integrated network account is supported by current data. Literature was identified through structured searching of biomedical and multidisciplinary scholarly sources, supplemented by citation tracking and examination of recent reviews and clinical guidelines, with appraisal weighted towards mechanistic specificity, replication, and the distance between surrogate and clinical endpoints. Four themes emerge. First, natriuretic peptide biology provides the clearest example of an endocrine function of the heart, with reproducible lipolytic, thermogenic and insulin-sensitising actions in human tissue, although causal inference for metabolic protection rests mainly on genetic and animal evidence. Second, hormonal control of physiological cardiac growth during exercise, postnatal maturation and pregnancy is mechanistically well defined but has not translated into usable therapy. Third, endocrine disease produces recognisable and often reversible cardiac phenotypes, whereas the converse relationship, in which cardiac disease disturbs hormonal regulation, has generated prognostic associations that have repeatedly failed to become successful treatment targets. Fourth, drugs developed for metabolic indications now deliver some of the clearest cardiac benefits, which suggests that the therapeutic value of this axis lies in metabolic and mineralocorticoid signalling rather than in classical hormone replacement. Important uncertainties persist concerning the direction of causality in low-triiodothyronine states, the clinical meaning of natriuretic peptide deficiency in obesity, and the interpretation of cardiokines as hormones rather than stress biomarkers. The reviewed evidence supports a regulated network rather than a hierarchy, but confidence varies sharply between its components, and several widely repeated mechanistic claims remain supported largely by preclinical work.
No takes yet. Share an insight, caveat, or question.
Soliman et al. (2026) conducted a review in Bidirectional heart-endocrine crosstalk in physiological adaptation and cardiovascular/endocrine disease. Bidirectional cardio-endocrine crosstalk operates as a regulated network where metabolic and mineralocorticoid-targeting drugs deliver clearer cardiac benefits than classical hormone replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: